

NCT03532620 comparison:

Summary:
CHIA has 23 criteria while your personal folder has 23 criteria
Total found criteria: 23/23
Total not Found: 0/23
Total Extra: 3
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Age 18-80 years old                                │ Age 18-80 years old                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ IFG: 5.6mmol/L (100mg/dl)=FPG<7.0mmol/L            │ IFG: 5.6mmol/L (100mg/dl)≤FPG\<7.0mmol/L           │
│ (126mg/dl), or IGT: 7.8mmol/L (140mg/dl)=OGTT 2-h  │ (126mg/dl), or IGT: 7.8mmol/L (140mg/dl)≤OGTT 2-h  │
│ PG<11.1mmol/L (200mg/dl), or HbA1C 5.7-6.4%        │ PG\<11.1mmol/L (200mg/dl), or HbA1C 5.7-6.4%       │
│ (39-47mmol/mol)                                    │ (39-47mmol/mol)                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ 6mmol/L (100mg/dl)=LDL-C=5.2mmol/L (200mg/dl), and │ 6mmol/L (100mg/dl)≤LDL-C≤5.2mmol/L (200mg/dl), and │
│ TG<5.7mmol/L (500mg/dl)                            │ TG\<5.7mmol/L (500mg/dl)                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ 130mmHg=SBP<180mmHg, or 80mmHg=DBP<110mmHg or      │ 130mmHg≤SBP\<180mmHg, or 80mmHg≤DBP\<110mmHg or    │
│ ongoing anti-hypertensive therapy                  │ ongoing anti-hypertensive therapy                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients volunteered for the study and signed      │ Patients volunteered for the study and signed      │
│ informed consent                                   │ informed consent                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Past history of hypersensitivity to the study drug │ Past history of hypersensitivity to the study drug │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosed diabetes                                 │ Diagnosed diabetes                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe liver disease (including ALT or             │ Severe liver disease (including ALT or             │
│ AST=2.5-fold the normal upper limit), biliary      │ AST≥2.5-fold the normal upper limit), biliary      │
│ obstruction                                        │ obstruction                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ongoing treatment with cyclosporine within 2 weeks │ Ongoing treatment with cyclosporine within 2 weeks │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Renal dysfunction, including endogenous creatinine │ Renal dysfunction, including endogenous creatinine │
│ clearance male<120ml/min, female<105ml/min, serum  │ clearance male\<120ml/min, female\<105ml/min,      │
│ creatinine=2mg/dl (186umol/L), Renal function      │ serum creatinine≥2mg/dl (186umol/L), Renal         │
│ progressive decline, GFR<30ml•min-1•1.73m-2        │ function progressive decline,                      │
│                                                    │ GFR\<30ml•min-1•1.73m-2                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosed or past history of ASCVD (including ACS, │ Diagnosed or past history of ASCVD (including ACS, │
│ SCAD, revascularization, ICM, ischemic stroke,     │ SCAD, revascularization, ICM, ischemic stroke,     │
│ TIA, PASD, etc                                     │ TIA, PASD, etc                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ SBP=180mmHg, or DBP=110mmHg                        │ SBP≥180mmHg, or DBP≥110mmHg                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ongoing treatment with Beta blockers, Diuretic     │ Ongoing treatment with Beta blockers, Diuretic     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Secondary hypertension, including SAS, PA, RAS,    │ Secondary hypertension, including SAS, PA, RAS,    │
│ pheochromocytoma, Cushing's syndrome, aorta        │ pheochromocytoma, Cushing's syndrome, aorta        │
│ diseases, drug induced hypertension                │ diseases, drug induced hypertension                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ongoing treatment with statins, fibrates, and/or   │ Ongoing treatment with statins, fibrates, and/or   │
│ cation exchange resins within 2 weeks              │ cation exchange resins within 2 weeks              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pancreatic disease                                 │ Pancreatic disease                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of gastrectomy, short bowel syndrome       │ History of gastrectomy, short bowel syndrome       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ongoing hormone replacement therapy                │ Ongoing hormone replacement therapy                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosed or suspected malignant tumor             │ Diagnosed or suspected malignant tumor             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Familial hypercholesterolemia                      │ Familial hypercholesterolemia                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any diseases may limit the efficacy or safety of   │ Any diseases may limit the efficacy or safety of   │
│ the study                                          │ the study                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant or possibly pregnant woman, or            │ Pregnant or possibly pregnant woman, or            │
│ breastfeeding woman, or woman who wishes to become │ breastfeeding woman, or woman who wishes to become │
│ pregnant during study participation                │ pregnant during study participation                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ IFG impaired fast glucose, FPG fasting plasma      │ IFG impaired fast glucose, FPG fasting plasma      │
│ glucose, IGT impaired glucose tolerance, OGTT oral │ glucose, IGT impaired glucose tolerance, OGTT oral │
│ glucose tolerance test, PG plasma glucose, HbA1C   │ glucose tolerance test, PG plasma glucose, HbA1C   │
│ hemoglobin A1C, LDL-C low-density lipoprotein      │ hemoglobin A1C, LDL-C low-density lipoprotein      │
│ cholesterol, TG triglycerides, SBP systolic blood  │ cholesterol, TG triglycerides, SBP systolic blood  │
│ pressure, DBP diastolic blood pressure, ALT        │ pressure, DBP diastolic blood pressure, ALT        │
│ alanine aminotransferase, AST aspartate            │ alanine aminotransferase, AST aspartate            │
│ aminotransferase, GFR glomerular filtration rate,  │ aminotransferase, GFR glomerular filtration rate,  │
│ ASCVD arteriosclerotic cardiovascular disease, ACS │ ASCVD arteriosclerotic cardiovascular disease, ACS │
│ acute coronary syndrome, SCAD stable coronary      │ acute coronary syndrome, SCAD stable coronary      │
│ artery disease, ICM ischemic cardiomyopathy, TIA   │ artery disease, ICM ischemic cardiomyopathy, TIA   │
│ transient ischemic attack, PASD peripheral         │ transient ischemic attack, PASD peripheral         │
│ atherosclerotic disease, SAS sleep apnea syndrome, │ atherosclerotic disease, SAS sleep apnea syndrome, │
│ PA primary aldosteronism, RAS renal arterial       │ PA primary aldosteronism, RAS renal arterial       │
│ stenosis                                           │ stenosis                                           │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                   │
╞═══════════════════════════════════════════════════════════════════════════╡
│ Patient who was not judged as eligible by the investigator/coinvestigator │
├───────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                         │
├───────────────────────────────────────────────────────────────────────────┤
│ Must have maximum age of 80 Years                                         │
╘═══════════════════════════════════════════════════════════════════════════╛